Submitted:
19 February 2025
Posted:
20 February 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Study Group Selection
- Have had zero doses of an approved HPV vaccine
- At least 20 years old and born in 1997 or later
- Female sex, as identified on their Manitoba Health card
- Valid Manitoba health insurance coverage and a complete Manitoba mailing address
- Have received one or more doses of an approved HPV vaccine
- Have had cervical cancer
- Have had a hysterectomy
- In active colposcopy treatment
2.2. Mail-Outs
2.3. Assessing Intervention Response
3. Results
3.1. Cohort Demographics
3.2. Six-Month HPV Vaccine Uptake
3.3. Twelve-Month HPV Vaccine Uptake
4. Discussion
4.1. Main Findings
4.2. Strengths and Limitations
4.3. Future Directions
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- National Advisory Committee on Immunization. Updated Recommendations on Human Papillomavirus (HPV) Vaccines: 9-valent HPV vaccine and clarification of minimum intervals between doses in the HPV immunization schedule. Public Health Agency of Canada: Ottawa, Canada, 2017.
- Canadian Cancer Society. Compare Study. The attributable risk of cancer in Canada. Available online: https://prevent.cancer.ca/ (accessed July 2024).
- Statistics Canada. Manitoba Population and dwelling counts. Focus on Geography Series, 2021 Census of Population. Available online: https://www12.statcan.gc.ca/census-recensement/2021/as-sa/fogs-spg/index.cfm (accessed July 2024).
- Manitoba Health and Seniors Care. Manitoba's School Immunization Program: Questions & Answers for Health Care Providers. Government of Manitoba. Accessed online: https://www.gov.mb.ca/health/publichealth/factsheets/mb_school_imms.pdf (accessed July 2024).
- Province of Manitoba. Manitoba's Immunization Program: Vaccines Offered Free-of-Charge. Available online: https://www.gov.mb.ca/health/publichealth/cdc/vaccineeligibility.html (accessed July 2024).
- Canadian Partnership Against Cancer. Eliminating cervical cancer in Canada: Improving HPV vaccination rates. Canadian Partnership Against Cancer. Available online: https://www.partnershipagainstcancer.ca/topics/eliminating-cervical-cancer/hpv-vaccination/ (accessed July 2024).
- Manitoba Health. Annual Report of Immunization Surveillance: Public Health Information Management System. Manitoba. Available online: https://www.gov.mb.ca/health/publichealth/surveillance/immunization/index.html (accessed July 2024).
- CancerCare Manitoba. HPV vaccine data in CervixCheck registry. Winnipeg, Canada: unpublished data, 2022.
- Bonfill X, Marzo M, Pladevall M, Martí J, Emparanza JI. Strategies for increasing women participation in community breast cancer screening. Cochrane Database Systematic Reviews January 2001. CD002943.
- E. Ferroni, L. Camilloni, B. Jimenez, G. Furnari, P. Borgia, G. Guasticchi, P. Giorgi Rossi. How to increase uptake in oncologic screening: A systematic review of studies comparing population-based screening programs and spontaneous access. Preventive Medicine, 2012, Vol. 55, pp. 587-596. [CrossRef]
- Jager M, Demb J, Asghar A, Selby K, Marquez Mello E, Heskett KM, Lieverman AJ, geng Z, Bharti B, Singh S, Gupta S. Mailed Outreach Is Superior to Usual Care Alone for Colorectal Cancer Screening in the USA: A Systematic Review and Meta-analysis. Dig Dis Sci, March 2019, Vol. 64, pp. 2489-2496. [CrossRef]
- Staley, Helen, et al. Interventions targeted at women to encourage the uptake of cervical screening. Cochrane Database of Systematic Reviews 2021 1465-1858.
- Dougherty MK, Brenner AT, Crockett SD, Gupta S, Wheeler SB, Coker-Schwimmer M, Cubillos L, Malo T, Reuland DS. Evaluation of Interventions Intended to Increase Colorectal Cancer Screening Rates in the United States: A Systematic Review and Meta-analysis. JAMA Intern Med 2018, 178, 1645–1658. [CrossRef] [PubMed]
- Camilloni L, Ferroni E, Cendales BJ, Pezzarossi A, Furnari G, Borgia P, Guasticchi G, Giorgi Rossi P and Methods to increase participation Working Group. Methods to increase participation in organised screening programs: a systematic review. BMC Public Health, 2013, Vol. 13. [CrossRef]
- Jacobson Vann JC, Jacobson RM, Coyne-Beasley T, Asafu-Adjei JK, Szilagyi PG. Patient reminder and recall interventions to improve immunization rates. Cochrane Database of Systematic Reviews, January 2018. [CrossRef]
- Szilagyi PG, Bordley C, Vann JC, Chelminski MD, Kraus RM, Margolis PA, Rodewald, LE. Effect of Patient Reminder/Recall Interventions on Immunization Rates: A Review. JAMA, 2000, Vol. 284, pp. 1820-1827. [CrossRef]
- World Health Organization. Cervical Cancer Elimination Initiative. World Health Organization. Available online: https://www.who.int/initiatives/cervical-cancer-elimination-initiative (accessed July 2024).


| Control Group (No Study-Specific Letters) |
Intervention Group I: Invitation Letter |
Intervention Group II: Invitation Letter and Reminder Letter |
|
| Average age Age range |
23.1 years 20-26 years |
23.1 years 20-26 years |
23.2 years 20-26 years |
| Living in a rural region of the province | 23.4 % | 24.4% | 25.5% |
| Unscreened for cervical cancer* | 72.8% | 74.3% | 72.7% |
| Control Group (No Study-Specific Letters) |
Intervention Group I: Invitation Letter |
Intervention Group II: Invitation Letter and Reminder Letter |
|
| Group size (met inclusion and exclusion criteria over six months of follow-up) | 4,458 | 4,210 | 4,185 |
| Received at least one dose of the HPV vaccine within six months of invitation sent date | 38 (0.9%) |
107 (2.5%) |
168 (4.0%) |
| Control group vs. intervention group I: Invitation letter | Control group vs. intervention group II: Invitation and reminder letters | |
| Odds ratio estimates | 3.0 | 4.9 |
| 95% Wald confidence limits | 2.1 - 4.4 | 3.4 - 6.9 |
| P-value | <0.001 | <0.001 |
| Control Group (No Study-Specific Letters) |
Intervention Group I: Invitation Letter |
Intervention Group II: Invitation Letter and Reminder Letter |
|
| Group size (met inclusion and exclusion criteria) over 12 months of follow-up | 4,430 | 4,191 | 4,167 |
| Received at least one dose of the HPV vaccine within twelve months of invitation sent date | 74 (1.7%) |
157 (3.7%) |
215 (5.2%) |
| Control group vs. intervention group I: Invitation letter | Control group vs. intervention group II: Invitation and reminder letters | |
| Odds ratio estimates | 2.3 | 3.2 |
| 95% Wald confidence limits | 1.7 - 3.0 | 2.5 - 4.2 |
| P-value | <0.001 | <0.001 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).